FrancophonIA/ELRC3.0 huggingface dataset:
English: Following 52 weeks and 104 weeks of treatment, the percentage of patients without progression (change from baseline in modified Total Sharp Score ≤ 0.5) was significantly higher with adalimumab/methotrexate combination therapy (63.8% and 61.2% respectively) compared to methotrexate monotherapy (37.4% and 33.5% respectively, p < 0.001) and adalimumab monotherapy (50.7%, p < 0.002 and 44.5%, p < 0.001 respectively).
Danish: Efter henholdsvis 52 ugers og 104 ugers behandling, var procentdelen af patienter uden progression (ændring fra baseline i modificeret Total Sharp Score ≤ 0,5) signifikant højere med adalimumab/methotrexat-kombinationsterapi (henholdsvis 63,8 % og 61,2 %) sammenlignet med methotrexat-monoterapi (henholdsvis 37,4 % og 33,5 %, p<0,001) og adalimumab monoterapi (henholdsvis 50,7 %, p<0,002 og 44,5 %, p<0,001).
English: • opportunistic infections (which include tuberculosis and other infections that occur when resistance to disease is lowered);
Danish: • opportunistiske infektioner (som inkluderere tuberkulose og andre infektioner, som forekommer,
English: The most commonly reported adverse reactions are infections (such as nasopharyngitis, upper respiratory tract infection and sinusitis), injection site reactions (erythema, itching, haemorrhage, pain or swelling), headache and musculoskeletal pain.
Danish: De hyppigst rapporterede bivirkninger er infektioner (såsom nasopharyngitis, øvre luftvejsinfektioner og sinuitis), reaktioner på injektionsstedet (erytem, kløe, blødning, smerter eller hævelse), hovedpine og muskuloskeletale smerte.
English: Patients should be instructed to seek medical advice if signs/symptoms suggestive of a tuberculosis infection (e.g. persistent cough, wasting/weight loss, low grade fever, listlessness) occur during or after therapy with AMGEVITA.
Danish: Patienter bør instrueres i at søge læge, hvis der opstår sygdomstegn/symptomer, der tyder på tuberkulose (f.eks. vedvarende hoste, tæring/vægttab, lav feber, apati) under eller efter behandling med AMGEVITA.
English: Patients induced with 160/80 mg adalimumab achieved clinical remission versus placebo at week 8 in statistically significantly greater percentages in study UC-I (18% versus 9% respectively, p = 0.031) and study UC-II (17% versus 9% respectively, p = 0.019).
Danish: I forhold til placebo opnåede en statistisk signifikant større procentdel af de patienter, der blev induceret med 160/80 mg adalimumab, klinisk remission i uge 8 (studie UC-I: henholdsvis 18 % og 9%, p=0,031; studie UC-II: henholdsvis 17 % og 9%, p=0,019).
English: Efficacy response in placebo-controlled Study nr-axSpA I Double-Blind Response at week
Danish: Respons på effektmål i placebo-kontrolleret studie nr-axSpA I Dobbelt-blind respons ved uge 12
English: Clinical response is decrease from baseline in Mayo score ≥ 3 points and ≥ 30% plus a decrease in the rectal bleeding subscore [RBS] ≥ 1 or an absolute RBS of 0 or 1; * p < 0.05 for adalimumab versus placebo pairwise comparison of proportions ** p < 0.001 for adalimumab versus placebo pairwise comparison of proportions a Of those receiving corticosteroids at baseline
Danish: Klinisk respons er fald fra baseline i Mayo score på ≥ 3 point og ≥ 30 % samt et fald i rektal blødning-subscore [RBS] på ≥ 1 eller en absolut RBS på 0 eller 1; *p < 0,05 for adalimumab versus placebo ved parvis sammeligning af andelene **p < 0,001 for adalimumab versus placebo ved parvis sammeligning af andelene a Af de patienter, der fik steroid ved baseline
English: • heart problems that can cause shortness of breath or ankle swelling;
Danish: • hjerteproblemer, som kan forårsage kortåndethed og hævede ankler,
English: These trials included rheumatoid arthritis patients with short term and longstanding disease, juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and enthesitisrelated arthritis) as well as axial spondyloarthritis (ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of AS), psoriatic arthritis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa and uveitis patients.
Danish: Disse studier omfattede patienter med reumatoid artrit af kortere og længere sygdomsvarighed, uvenil idiopatisk artrit (polyartikulær juvenil idiopatiske artrit og entesopatirelateret artrit) og patienter med aksial spondyloartritis (ankyloserende spondylitis og aksial spondyloartritis uden radiografiske tegn på ankyloserende spondylitis (AS)), psoriasisartrit, Crohns sygdom, colitis ulcerosa, psoriasis, hidrosadenitis suppurativa og uveitis.
English: Aortic aneurysm, Vascular arterial occlusion, Thrombophlebitis
Danish: Ikke almindelig Aorta-anurisme, Vaskulær arteriel okklusion, Tromboflebit
English: • mood swings (including depression);
Danish: • humørsvingninger (inklusive depression),
English: Dosing Regimen
Danish: Doseringsregime
English: Two weeks later (day 29) continue with a dose of 40 mg every week or 80 mg every other week (given as two 40 mg injections in one day).
Danish: To uger senere (Dag 29) fortsættes med en dosis på 40 mg hver uge eller 80 mg hver anden uge (givet som to injektioner af 40 mg på en dag).
English: p-valuea p-valueb p-valuec
Danish: p-værdia p-værdib p-værdic
English: Standard dose
Danish: Standard- dosis
English: For patients who stayed on their randomised therapy, the mean (±SD) adalimumab trough concentrations at week 52 were 9.5 ± 5.6 μg/mL for the standard dose group and 3.5 ± 2.2 μg/mL for the low dose group.
Danish: Hos patienter, som blev på deres randomiserede behandling, var den gennemsnitlige dal-koncentration (±SD) af adalimumab 9,5±5,6 µg/ml for standard-dosis-gruppen og 3,5±2,2 µg/ml for lav-dois-gruppen ved uge 52.
English: What AMGEVITA contains - The active substance is adalimumab.
Danish: AMGEVITA indeholder - Aktivt stof: adalimumab.
English: Erythema multiforme1), Stevens-Johnson syndrome1), Angioedema1), Cutaneous vasculitis1) Lichenoid skin reaction1)
Danish: Erythema multiforme1), Stevens-Johnsons syndrom1), Angioødem1),
English: The recommended AMGEVITA induction dose regimen for adult patients with moderately to severely active Crohn's disease is 80 mg at week 0 followed by 40 mg at week 2.
Danish: Det anbefalede AMGEVITA induktions-dosis-regime til voksne patienter med moderat til svær aktiv Crohns sygdom er 80 mg i uge 0 efterfulgt af 40 mg i uge 2.
English: During the controlled portions of pivotal adalimumab trials in adults of at least 12 weeks in duration in patients with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of AS, psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn's disease, ulcerative colitis and uveitis, malignancies, other than lymphoma and non-melanoma skin cancer, were observed at a rate (95% confidence interval) of 6.8 (4.4, 10.5) per 1,000 patient-years among 5,291 adalimumab-treated patients versus a rate of 6.3 (3.4, 11.8) per 1,000 patient-years among 3,444 control patients (median duration of treatment was 4.0 months for adalimumab and 3.8 months for control-treated patients).
Danish: I de kontrollerede dele af de pivotale adalimumab-studier med voksne af mindst 12 ugers varighed hos patienter med moderat til svær aktiv reumatoid artrit, ankyloserende spondylitis, aksial spondyloartritis uden radiografiske tegn på AS, psoriasisartrit, psoriasis, hidrosadenitis suppurativa, Crohns sygdom, colitis ulcerosa og uveitis blev der observeret maligniteter, fraset lymfomer eller ikke-melanom hudkræft, med en hyppighed (95 % konfidensinterval) på 6,8 (4,4-10,5) pr. 1.000 patientår bandt 5.291 adalimumab-behandlede patienter mod en hyppighed på 6,3 (3,4-11,8) pr. 1.000 patientår blandt 3.444 kontrolpatienter (gennemsnitlig varighed af behandlingen var 4,0 måneder for adalimumab og 3,8 måneder for de kontrol-behandlede patienter).
English: ACR response in placebo-controlled psoriatic arthritis studies (percent of patients)
Danish: ACR-respons i placebokontrollerede psoriasisartrit-studier (procentdel af patienter)
English: Solid organ neoplasm (including breast cancer, lung neoplasm and thyroid neoplasm), Melanoma**
Danish: Ikke almindelig Lymfom**, Solide organ-neoplasmer (inklusive brystkræft, lungekræft og thyroideakræft), Melanom**
English: • increased sweating;
Danish: • øget svedtendens,
English: The needle cover of the pre-filled pen is made from dry natural rubber (a derivative of latex), which may cause allergic reactions.
Danish: Den fyldte pennens kanylehætte er fremstillet af tørt naturgummi (et derivat af latex), som kan medføre allergiske reaktioner.
English: The safety and efficacy of adalimumab was assessed in a randomised, double-masked, controlled study of 90 paediatric patients from 2 to < 18 years of age with active JIA-associated noninfectious anterior uveitis who were refractory to at least 12 weeks of methotrexate treatment.
Danish: Adalimumabs sikkerhed og virkning undersøgt i et randomiseret, dobbeltblindet, kontrolleret studie hos 90 pædiatriske patienter fra 2 til < 18 år med aktiv JIA-associeret non-infektiøs anterior uveitis, som var refraktære overfor mindst 12 ugers behandling med methotrexat.
English: • sensation disorders such as tingling, prickling or numbness;
Danish: • følelsesforstyrrelser såsom snurren, prikken eller følelsesløshed,
English: • autoantibodies present in the blood;
Danish: • tilstedeværelse af autoantistoffer i blodet,
English: No clinical data are available on the use of a AMGEVITA loading dose in children < 6 years of age (see section 5.2).
Danish: Der foreligger ingen kliniske data om brugen af en AMGEVITA-induktionsdosis til børn < 6 år (se pkt.
English: Medicine Make sure the medicine in the window is clear and colourless to slightly yellow.
Danish: Medicin Kontrollér, at medicinen i ruden er klar og farveløs til lysegul.
English: Adalimumab 40 mg every other week was assessed in 393 patients in two randomised, 24 week double-blind, placebo-controlled studies in patients with active ankylosing spondylitis (mean baseline score of disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] was 6.3 in all groups) who have had an inadequate response to conventional therapy.
Danish: Adalimumab 40 mg hver anden uge blev undersøgt i to randomiserede, 24 ugers dobbelt-blinde placebo-kontrollerede studier med 393 patienter med aktiv ankyloserende spondylitis (gennemsnits score ved baseline for sygdomsaktivitet [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] var 6,3 i alle grupper), som ikke havde responderet tilstrækkeligt på konventionel behandling.
English: No ALT elevations ≥ 3 X ULN occurred in the phase 3 trial of adalimumab in paediatric patients with plaque psoriasis.
Danish: Der forekom ingen ALAT-stigninger ≥ 3 x ULN i fase 3-studier af adalimumab hos pædiatriske patienter med plaque-psoriasis.
English: Each pack contains 1, 2, 4 or 6 single-use 40 mg pre-filled syringes (with blue plunger rod).
Danish: Hver pakning indeholder 1, 2, 4 eller 6 40 mg fyldte injektionssprøjter til engangsbrug (med blå stempelstang).
English: F. Pinch your injection site to create a firm surface.
Danish: F. Klem sammen om injektionsstedet, så der dannes et fast underlag.
English: Methotrexate should be continued during treatment with AMGEVITA.
Danish: Der fortsættes med methotrexat under behandling med AMGEVITA.
English: After two further weeks, continue with a dose of 40 mg every week or 80 mg every other week, as prescribed by your doctor.
Danish: Efter yderligere 2 uger fortsættes med 40 mg hver uge eller 80 mg hver anden uge, alt efter lægens ordination.
English: ● Do not use an AMGEVITA pre-filled syringe if it has been dropped on a hard surface.
Danish: ● Brug ikke en fyldt injektionssprøjte, hvis den har været tabt på en hård flade.
English: Grab the syringe barrel to remove the syringe from the tray.
Danish: Tag fat i sprøjtehuset for at få sprøjten ud af bakken.
English: Adalimumab treatment reduced the rate of progression of peripheral joint damage compared with placebo treatment as measured by change from baseline in mTSS (mean ± SD) 0.8 ± 2.5 in the placebo group (at week 24) compared with 0.0 ± 1.9; (p < 0.001) in the adalimumab group (at week 48).
Danish: Sammenlignet med placebo reducerede adalimumab progressionshastigheden, hvormed de perifere led destrueres, målt ved ændring i mTSS fra baseline (gennemsnit + SD) 0,8 ± 2,5 i placebogruppen (ved uge 24) sammenlignet med 0,0 ± 1,9 i adalimumab-gruppen (ved uge 48) (p<0,001).
English: AMGEVITA is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.
Danish: AMGEVITA er indiceret til behandling af moderat til svær kronisk plaque-psoriasis hos voksne patienter, hvor systemisk behandling er relevant.
English: Adalimumab treated patients showed statistically significant improvements at week 26 compared with placebo in the DLQI.
Danish: Adalimumab-behandlede patienter viste statistisk signifikante forbedringer i DLQI ved uge 26 sammenlignet med placebo.
English: Multipack: 6 (3 packs of 2) pre-filled syringes.
Danish: Multipakning: 6 (3 pakninger á 2) fyldte injektionssprøjter.
English: For a more comfortable injection, leave the pre-filled pen at room temperature for 15 to 30 minutes before injecting.
Danish: For at injektionen skal være mere behagelig, kan du tage pennen ud og opbevare den ved stuetemperatur 15 til 30 minutter inden injektionen.
English: a RA study I at 24 weeks, RA study II at 26 weeks, and RA study III at 24 and 52 weeks b 40 mg adalimumab administered every other week c MTX = methotrexate ** p < 0.01, adalimumab versus placebo
Danish: NA NA NA 4,5 % 23,2% a RA-studie I efter 24 uger, RA-studie II efter 26 uger og RA-studie III efter 24 og 52 uger b 40 mg adalimumab givet hver anden uge c MTX = methotrexat **p < 0,01, adalimumab versus placebo
English: • high blood measurements for lactate dehydrogenase;
Danish: • høje blodmålinger af lactatdehydrogenase,
English: Approximately twice the proportion of patients in the placebo group in the first 12 weeks of Studies HS-I and HS-II, compared with those in the adalimumab group experienced worsening of abscesses (23.0% versus 11.4%, respectively) and draining fistulas (30.0% versus 13.9%, respectively).
Danish: Ca. dobbelt så mange patienter i placebo-gruppen som i adalimumabgruppen oplevede forværring af abscesser (henholdvis 23,0% versus 11,4%) og suppurerende fistler (henholdvis 30,0% versus 13,9%) i de første 12 uger af HS-studie I og II.
English: • respiratory tract infections (including cold, runny nose, sinus infection, pneumonia);
Danish: • luftvejsinfektioner (inklusive forkølelse, løbende næse, bihulebetændelse, lungebetændelse),
English: The mean (±SD) serum adalimumab trough concentrations achieved at week 4 were 15.7 ± 6.6 μg/mL for patients ≥ 40 kg (160/80 mg) and 10.6 ± 6.1 μg/mL for patients < 40 kg (80/40 mg).
Danish: De gennemsnitlige dal-serumkoncentrationer (±SD) af adalimumab, som blev opnået ved uge 4, var 15,7±6,6 µg/ml for patienter ≥ 40 kg (160/80 mg) og 10,6±6,1 µg/ml for patienter < 40 kg (80/40 mg).
English: After 12 weeks of therapy, patients who had received adalimumab in Period A were rerandomised in Period B to 1 of 3 treatment groups (adalimumab 40 mg every week, adalimumab 40 mg every other week, or placebo from week 12 to week 35).
Danish: Efter 12 ugers behandling blev patienterne, som havde fået adalimumab i periode A, randomiseret igen i periode B til 1 af 3 behandlingsgrupper (adalimumab 40 mg hver uge, adalimumab 40 mg hver anden uge eller placebo fra uge 12 til uge 35).
English: In CD study II, 325 patients who had lost response or were intolerant to infliximab were randomised to receive either 160 mg adalimumab at week 0 and 80 mg at week 2 or placebo at weeks 0 and 2.
Danish: I CD-studie II GAIN blev 325 patienter, der ikke længere responderede eller var intolerante over for infliximab, randomiseret til at få enten 160 mg adalimumab i uge 0 og 80 mg i uge 2 eller placebo i uge 0 og 2.
English: Antibiotics may be continued during treatment with AMGEVITA if necessary.
Danish: Hvis det er nødvendigt, kan behandling med antibiotika fortsættes under AMGEVITA-behandlingen.
English: Available data suggest that the clinical response is usually achieved within 12 weeks of treatment.
Danish: Tilgængelige data tyder på, at klinisk respons sædvanligvis opnås inden for 12 uger.
English: After single intravenous doses ranging from 0.25 to 10 mg/kg,
Danish: Efter enkeltvise intravenøse doser på mellem 0,25 og 10 mg/kg var koncentrationerne dosisrelaterede.
English: Blood lactate dehydrogenase increased
Danish: Forhøjet blodlactatdehydrogenase
English: 40 mg adalimumab every week
Danish: 40 mg Adalimumab hver uge
English: Adequate data from treating patients who are carriers of HBV with anti-viral therapy in conjunction with TNF-antagonist therapy to prevent HBV reactivation are not available.
Danish: Der foreligger ikke tilstrækkelige data fra anti-viral behandling i kombination med TNFantagonister for at forebygge HBV-reaktivering hos patienter, som er bærere af.
English: Place your finger or thumb on edge of tray to secure it while you remove the syringe.
Danish: Sæt en finger på kanten af bakken for at holde bakken fast, mens du tager sprøjten ud.
English: In all cases, use a new syringe.
Danish: Brug i alle disse tilfælde en ny injektionssprøjte.
English: EU/1/16/1164/005 - 6 (3x2) multipack AMGEVITA 40 mg solution for injection in pre-filled pen EU/1/16/1164/006 - 1 pack
Danish: EU/1/16/1164/005 - multipakning med 6 (3x2) AMGEVITA 40 mg injektionsvæske, opløsning i fyldt pen EU/1/16/1164/006 - pakning med 1
English: vision related effects were not numerically in favour of adalimumab for colour vision in study UVI and for colour vision, peripheral vision and near vision in study UV II.
Danish: For synsrelaterede effekter havde adalimumab ikke numererisk en fordel ved farvesyn i Studie UV I og ved farvesyn, langsyn og nærsyn i studie UV II.
English: Efficacy Outcomes
Danish: Effekt-resultater
English: • intestinal infections (including gastroenteritis);
Danish: • tarminfektioner (inklusive gastroenteritis)
English: AMGEVITA is injected under the skin (subcutaneous use).
Danish: AMGEVITA injiceres under huden (subkutan anvendelse).
English: ● Do not shake the pre-filled pen.
Danish: ● Ryst ikke den fyldte pen.
English: 1 SureClick pre-filled pen.
Danish: 1 SureClick fyldt pen.
English: AMGEVITA is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate.
Danish: AMGEVITA er indiceret til behandling af voksne med non-infektiøs intermediær, posterior og panuveitis, som har haft utilstrækkeligt respons på kortikosteroider, som har behov for kortikosteroidbesparende behandling, eller som ikke er egnet til behandling med kortikosteroider.
English: Pack sizes of one, two, four or multipack of six (3x2) pre-filled pens.
Danish: Pakningsstørrelser med én, to, fire eller multipakning med seks (3x2) fyldte penne.
English: Important: Always keep the sharps disposal container out of the sight and reach of children.
Danish: Vigtigt: Opbevar altid kanylebøtten utilgængeligt for børn.
English: AMGEVITA is used to treat rheumatoid arthritis in adults.
Danish: AMGEVITA bruges til at behandle reumatoid artrit hos voksne.
English: In an analysis in which all patients who dropped out of the study for adverse events or lack of efficacy, or who dose-escalated, were considered non-responders, PASI 75 and PGA of clear or minimal response rates in these patients were 69.6% and 55.7%, respectively, after an additional 108 weeks of open-label therapy (total of 160 weeks).
Danish: I en analyse af non-respondenter, defineret som patienter, som udgik af studiet på grund af bivirkninger eller manglende effekt, eller hvor dosis blev trappet op var PASI 75- og PGA clear/minimal responserater henholdvis 69,6 % og 55,7 % efter yderligere 108 ugers åben-behandling (i alt 160 uger).
English: Week 12 results showed statistically significant improvement of the signs and symptoms of active nr-axSpA in patients treated with adalimumab compared to placebo (table 14).
Danish: Resultaterne i uge 12 viste statististisk signifikante forbedringer på tegn og symptomer på aktiv nr-axSpA hos patienter i behandling med adalimumab sammenlignet med placebo (Tabel 14).
English: Make sure the medicine in the syringe is clear and colourless to slightly yellow.
Danish: Kontrollér, at medicinen i sprøjten er klar og farveløs til lysegul.
English: Pleural effusion1)
Danish: Pleuraeffusion1)
English: After week 2, patients in both adalimumab arms received 40 mg every other week.
Danish: Efter uge 2 fik patienterne i begge adalimumab-arme 40 mg hver anden uge.
English: Patients demonstrating a paediatric ACR 30 response at week 16 were eligible to be randomised into the double blind (DB) phase and received either adalimumab 24 mg/m2 up to a maximum of 40 mg, or placebo every other week for an additional 32 weeks or until disease flare.
Danish: Patienter, der udviste pædiatrisk ACR 30-respons ved uge 16, var egnede til randomisering i den dobbeltblindede fase og fik enten adalimumab 24 mg/m2 op til maksimalt 40 mg eller placebo hver anden uge i yderligere 32 uger eller indtil opblussen af sygdommen.
English: It is recommended that paediatric patients, if possible, be brought up to date with all immunisations in agreement with current immunisation guidelines prior to initiating AMGEVITA therapy.
Danish: Før behandling med AMGEVITA påbegyndes, anbefales det, hvis det er muligt, at bringe pædiatriske patienter ajour med alle immuniseringer i overenstemmelse med gældende immuniseringsvejledninger.
English: The efficacy of adalimumab was assessed in a randomised, double-blind, controlled study of 114 paediatric patients from 4 years of age with severe chronic plaque psoriasis (as defined by a PGA ≥ 4 or > 20% BSA involvement or > 10% BSA involvement with very thick lesions or PASI ≥ 20 or ≥ 10 with clinically relevant facial, genital, or hand/foot involvement) who were inadequately controlled with topical therapy and heliotherapy or phototherapy.
Danish: Adalimumabs virkning er undersøgt i et randomiseret, dobbelt-blindet kontrolleret studie med 114 pædiatriske patienter fra 4 år med svær kronisk plaque-psoriasis (defineret ved PGA (physician global assessment) ≥ 4 eller > 20 % BSA (body surface area)-involvering eller > 10 % BSA-involvering med meget tykke læsioner eller PASI (psoriasis area and severity index) ≥ 20 eller ≥ 10 med klinisk relevante manifestioner i ansigt, på kønsorganer eller hånd/fod), som ikke havde opnået tilstrækkelig kontrol med topikal behandling og helioterapi eller lysbehandling.
English: RA study I evaluated 271 patients with moderately to severely active rheumatoid arthritis who were ≥ 18 years old, had failed therapy with at least one disease-modifying, anti-rheumatic drug and had insufficient efficacy with methotrexate at doses of 12.5 to 25 mg (10 mg if methotrexate-intolerant) every week and whose methotrexate dose remained constant at 10 to 25 mg every week.
Danish: RA-studie I evaluerede 271 patienter, der var ≥ 18 år, med moderat til alvorlig aktiv reumatoid artrit, hvor behandling var mislykket med mindst ét sygdomsmodificerende antireumatisk lægemiddel, hvor methotrexat i doser på 12,5 til 25 mg (10 mg ved methotrexat-intolerans) hver uge havde haft utilstrækkelig effekt, og hvor methotrexat-dosen forblev konstant på 10 til 25 mg hver uge.